NVCT vs. URGN, NUVB, IOVA, ABUS, DAWN, GHRS, SION, STOK, CDXC, and XNCR
Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Urogen Pharma (URGN), Nuvation Bio (NUVB), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), ChromaDex (CDXC), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.
Nuvectis Pharma vs. Its Competitors
Nuvectis Pharma (NASDAQ:NVCT) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.
In the previous week, Urogen Pharma had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Urogen Pharma and 2 mentions for Nuvectis Pharma. Urogen Pharma's average media sentiment score of 0.00 beat Nuvectis Pharma's score of -0.25 indicating that Urogen Pharma is being referred to more favorably in the news media.
Nuvectis Pharma presently has a consensus target price of $17.00, suggesting a potential upside of 120.78%. Urogen Pharma has a consensus target price of $32.86, suggesting a potential upside of 143.57%. Given Urogen Pharma's higher probable upside, analysts clearly believe Urogen Pharma is more favorable than Nuvectis Pharma.
Nuvectis Pharma has a net margin of 0.00% compared to Urogen Pharma's net margin of -150.68%. Nuvectis Pharma's return on equity of -148.83% beat Urogen Pharma's return on equity.
Nuvectis Pharma has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.
96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 30.5% of Nuvectis Pharma shares are held by insiders. Comparatively, 5.1% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Nuvectis Pharma has higher earnings, but lower revenue than Urogen Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Urogen Pharma beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.
Get Nuvectis Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvectis Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:NVCT) was last updated on 7/4/2025 by MarketBeat.com Staff
